Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2.
COVID
COVID-19
SARS-CoV-2
adipokine
adiponectin
adipose tissue
beta cell failure
diabetes
hyperglycemia
insulin
insulin resistance
Journal
Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170
Informations de publication
Date de publication:
02 11 2021
02 11 2021
Historique:
received:
26
04
2021
revised:
15
07
2021
accepted:
13
09
2021
pubmed:
3
10
2021
medline:
3
10
2021
entrez:
2
10
2021
Statut:
ppublish
Résumé
Individuals infected with SARS-CoV-2 who also display hyperglycemia suffer from longer hospital stays, higher risk of developing acute respiratory distress syndrome (ARDS), and increased mortality. Nevertheless, the pathophysiological mechanism of hyperglycemia in COVID-19 remains poorly characterized. Here, we show that hyperglycemia is similarly prevalent among patients with ARDS independent of COVID-19 status. Yet among patients with ARDS and COVID-19, insulin resistance is the prevalent cause of hyperglycemia, independent of glucocorticoid treatment, which is unlike patients with ARDS but without COVID-19, where pancreatic beta cell failure predominates. A screen of glucoregulatory hormones revealed lower levels of adiponectin in patients with COVID-19. Hamsters infected with SARS-CoV-2 demonstrated a strong antiviral gene expression program in the adipose tissue and diminished expression of adiponectin. Moreover, we show that SARS-CoV-2 can infect adipocytes. Together these data suggest that SARS-CoV-2 may trigger adipose tissue dysfunction to drive insulin resistance and adverse outcomes in acute COVID-19.
Identifiants
pubmed: 34599884
pii: S1550-4131(21)00428-9
doi: 10.1016/j.cmet.2021.09.009
pmc: PMC8443335
mid: NIHMS1741989
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2174-2188.e5Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK121140
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK121844
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020541
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK121072
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215797
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : ErratumIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests R.E.S. is on the scientific advisory board of Miromatrix and is a speaker and consultant for Alnylam. The other authors have no competing interests.
Références
Cell Metab. 2020 Dec 1;32(6):1041-1051.e6
pubmed: 33207244
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
J Diabetes Investig. 2014 Sep;5(5):517-24
pubmed: 25411619
Sci Rep. 2021 Jan 15;11(1):1580
pubmed: 33452298
Cell Metab. 2021 Mar 2;33(3):479-498
pubmed: 33529600
Bioinformatics. 2005 Aug 15;21(16):3439-40
pubmed: 16082012
Lancet Diabetes Endocrinol. 2021 Feb;9(2):82-93
pubmed: 33357491
Nat Metab. 2020 Oct;2(10):1021-1024
pubmed: 32879473
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Int J Mol Sci. 2016 May 17;17(5):
pubmed: 27196896
Diabetologia. 2020 Oct;63(10):2102-2111
pubmed: 32647915
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Nutrients. 2019 Feb 22;11(2):
pubmed: 30813240
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Nat Protoc. 2009;4(8):1184-91
pubmed: 19617889
J Vis Exp. 2018 Jan 31;(131):
pubmed: 29443083
Lancet Infect Dis. 2021 Feb;21(2):203-212
pubmed: 33091374
Nat Med. 2019 Nov;25(11):1739-1747
pubmed: 31700183
Cell Metab. 2020 Dec 1;32(6):1028-1040.e4
pubmed: 33207245
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
N Engl J Med. 2019 May 23;380(21):1997-2008
pubmed: 31112383
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Sci (Lond). 2019 Nov 29;133(22):2317-2327
pubmed: 31769478
World J Diabetes. 2015 Jul 25;6(8):1073-81
pubmed: 26240704
Nat Metab. 2021 Jun;3(6):774-785
pubmed: 34035524
Ann Am Thorac Soc. 2017 Jan;14(1):124-133
pubmed: 27779896
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Crit Care. 2017 Mar 26;21(1):73
pubmed: 28342442
Nat Rev Dis Primers. 2015 Jul 23;1:15019
pubmed: 27189025
J Med Virol. 2021 Jan;93(1):409-415
pubmed: 32589756
Nat Rev Endocrinol. 2021 Jan;17(1):11-30
pubmed: 33188364
Cell Metab. 2021 Jan 5;33(1):65-77.e2
pubmed: 33248471
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Ann Am Thorac Soc. 2021 Nov;18(11):1849-1860
pubmed: 33760709
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
JCI Insight. 2018 May 3;3(9):
pubmed: 29720570
Nat Metab. 2021 Feb;3(2):123-125
pubmed: 33432203
Endocr J. 2011;58(4):315-22
pubmed: 21415555
Cell Metab. 2021 Aug 3;33(8):1577-1591.e7
pubmed: 34081913
J Biomed Inform. 2021 Jun;118:103789
pubmed: 33862230
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Viruses. 2020 Jun 06;12(6):
pubmed: 32517266
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
JCI Insight. 2018 Jun 7;3(11):
pubmed: 29875323
Ann Med. 2021 Dec;53(1):103-116
pubmed: 33063540
Ann Intern Med. 2020 Nov 17;173(10):855-858
pubmed: 32628537
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Genome Biol. 2019 Nov 14;20(1):238
pubmed: 31727128
Clin Infect Dis. 2021 Dec 6;73(11):e4197-e4205
pubmed: 32603425
AMIA Annu Symp Proc. 2018 Apr 16;2017:1581-1588
pubmed: 29854228
Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7
pubmed: 32579880
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Med (N Y). 2020 Dec 18;1(1):33-42
pubmed: 32838359
Nat Metab. 2021 Feb;3(2):149-165
pubmed: 33536639
Cell Metab. 2021 Aug 3;33(8):1565-1576.e5
pubmed: 34081912
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471